A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Biosense Webster, Inc.
- Study ID
- NCT06455098
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- OMNYPULSE™ Catheter with the TRUPULSE Generator — DEVICEOMNYPULSE™ Catheter and TRUPULSE™ Generator will be used for PF ablation.
Study Details
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Key Dates
- Start date
- Jun 28, 2024
- Status verified
- Mar 2026
- Primary completion
- May 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 440 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Pulsed Field (PF) Ablation SystemParticipants with PAF will undergo pulsed field ablation procedure with the OMNYPULSE™ catheter in combination with TRUPULSE™ generator for PVI and to deliver pulsed field (PF) energy for treatment of atrial fibrillation. Study participants will be followed for 12 months after the study index procedure.
Primary Outcome Measure
Number of Participants with Primary Adverse Events (PAEs) [ Time Frame: 7 days post-procedure ]
Central Contacts
- Study Contact949-789-3919
Locations (43)
Find similar trials in Phoenix, AZ
By condition
By specialty
By research site
Related Studies
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Boston, Massachusetts
- Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac SurgeryPHASE2 · Not Yet Recruiting · Baystate Medical Center · Melrose, Massachusetts
- Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial FibrillationPHASE4 · Recruiting · University of Illinois at Chicago · Chicago, Illinois
- Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot StudyPHASE2 · Recruiting · University of South Florida · Tampa, Florida